Capivasertib + Rabeprazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid and Hematological Malignancies
Conditions
Solid and Hematological Malignancies
Trial Timeline
Jul 26, 2021 → May 4, 2022
NCT ID
NCT04944771About Capivasertib + Rabeprazole
Capivasertib + Rabeprazole is a phase 1 stage product being developed by AstraZeneca for Solid and Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT04944771. Target conditions include Solid and Hematological Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04944771 | Phase 1 | Completed |
Competing Products
20 competing products in Solid and Hematological Malignancies